BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 8470432)

  • 1. Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine.
    Petersen JW; Andersen P; Ibsen PH; Capiau C; Wachmann CH; Hasløv K; Heron I
    Vaccine; 1993; 11(4):463-72. PubMed ID: 8470432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults.
    Tran Minh NN; He Q; Edelman K; Putto-Laurila A; Arvilommi H; Viljanen MK; Mertsola J
    Vaccine; 2000 Apr; 18(19):1971-4. PubMed ID: 10706957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
    Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
    J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens.
    Ausiello CM; Lande R; la Sala A; Urbani F; Cassone A
    J Infect Dis; 1998 Aug; 178(2):466-70. PubMed ID: 9697728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine.
    Berstad AK; Oftung F; Korsvold GE; Haugen IL; Froholm LO; Holst J; Haneberg B
    Vaccine; 2000 May; 18(22):2323-30. PubMed ID: 10738087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults.
    He Q; Tran Minh NN; Edelman K; Viljanen MK; Arvilommi H; Mertsola J
    Infect Immun; 1998 Aug; 66(8):3796-801. PubMed ID: 9673264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin.
    Blom J; Heron I; Hendley JO
    APMIS; 1994 Sep; 102(9):681-9. PubMed ID: 7946271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine.
    Watanabe M; Nagai M; Funaishi K; Endoh M
    Vaccine; 2000 Dec; 19(9-10):1199-203. PubMed ID: 11137257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine].
    Zakharova NS; Shmeleva EI; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Mertsalova NU; Britsina MV; Ermolova EV; Zaĭtsev EM
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):70-2. PubMed ID: 9304336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.
    Grimprel E; Bégué P; Anjak I; Njamkepo E; François P; Guiso N
    Clin Diagn Lab Immunol; 1996 Jan; 3(1):93-7. PubMed ID: 8770511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
    Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
    Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.
    Berstad AKH; Holst J; Frøholm LO; Haugen IL; Wedege E; Oftung F; Haneberg B
    J Med Microbiol; 2000 Feb; 49(2):157-163. PubMed ID: 10670566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of murine antibodies against whole-cell pertussis vaccine or filamentous haemagglutinin by Bordetella pertussis from patients with whooping cough.
    van den Berg BM; Beekhuizen H; Van Furth R; Mooi FR
    Scand J Immunol; 2000 May; 51(5):530-2. PubMed ID: 10792847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of pertussis toxin, filamentous haemagglutinin, 69 kDa outer membrane protein, agglutinogens 2 and 3 and lipopolysaccharide in the Danish whole-cell pertussis vaccine.
    Ibsen PH; Petersen JW; Heron I
    Vaccine; 1993; 11(3):318-22. PubMed ID: 8447160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
    Novotny P; Chubb AP; Cownley K; Charles IG
    Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
    Olander RM; Muotiala A; Karvonen M; Kuronen T; Runeberg-Nyman K
    Microb Pathog; 1990 Jan; 8(1):37-45. PubMed ID: 2159104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
    Boros CA; Hanlon M; Gold MS; Roberton DM
    Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.